Nicholas Investment Partners LP Purchases New Position in Eli Lilly and Company (LLY)

Nicholas Investment Partners LP purchased a new position in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 14,304 shares of the company’s stock, valued at approximately $1,203,000.

A number of other hedge funds also recently modified their holdings of LLY. Joel Isaacson & Co. LLC increased its stake in shares of Eli Lilly and by 1.5% in the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after buying an additional 50 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Eli Lilly and by 3.1% in the first quarter. Nisa Investment Advisors LLC now owns 324,377 shares of the company’s stock worth $27,280,000 after buying an additional 9,680 shares during the period. Washington Trust Bank increased its stake in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares during the period. Bollard Group LLC increased its stake in shares of Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock worth $26,408,000 after buying an additional 8,153 shares during the period. Finally, Sabal Trust CO increased its stake in shares of Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock worth $538,000 after buying an additional 75 shares during the period. 75.61% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE LLY) traded down 0.65% during midday trading on Thursday, reaching $82.03. 252,904 shares of the company’s stock traded hands. The stock has a 50-day moving average of $83.02 and a 200 day moving average of $81.68. The company has a market cap of $86.54 billion, a P/E ratio of 35.50 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72.

Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 earnings per share. On average, analysts anticipate that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is 90.04%.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/2797227/nicholas-investment-partners-lp-purchases-new-position-in-eli-lilly-and-company-lly.html.

LLY has been the subject of a number of research reports. BMO Capital Markets set a $71.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a report on Monday, July 17th. Credit Suisse Group reissued an “outperform” rating and issued a $87.00 price target on shares of Eli Lilly and in a report on Wednesday, April 19th. Jefferies Group LLC reissued a “buy” rating and issued a $92.00 price target (down from $94.00) on shares of Eli Lilly and in a report on Saturday, April 29th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $88.27.

In other news, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 669,733 shares of company stock valued at $55,845,287. Insiders own 0.20% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.